Letters1 December 2009Is Lifelong Anticoagulation Worth the Risk in Patients With Unprovoked DVT?Samuel Z. Goldhaber, MDSamuel Z. Goldhaber, MDFrom Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-151-11-200912010-00028 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:PREVENT studied the optimal management of patients with an initial idiopathic and unprovoked VTE. Although PREVENT was not powered to assess mortality, the data monitoring and safety board terminated the study early because of the marked reduction in recurrent VTE in the low-intensity warfarin group (target international normalized ratio, 1.5 to 2.0) compared with the placebo group. I am not aware of any cancer risk with warfarin, which has been available in the United States since 1954. The long-term risk for recurrent VTE after an initial DVT or pulmonary embolism is high, about 30% 10 years after discontinuation ... Author, Article, and Disclosure InformationAuthors: Samuel Z. Goldhaber, MDAffiliations: From Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOptimal Duration of Anticoagulation After Venous Thromboembolism: Fixed and Evidence-Based, or Flexible and Personalized? Samuel Z. Goldhaber Is Lifelong Anticoagulation Worth the Risk in Patients With Unprovoked DVT? Ferdinando Cortese Metrics 1 December 2009Volume 151, Issue 11Page: 827KeywordsConflicts of interestInternational normalized ratioMortalityPulmonary embolismSafetySafety studies ePublished: 1 December 2009 Issue Published: 1 December 2009 Copyright & PermissionsCopyright © 2009 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...